fda advisory committee for pharmaceutical science—march 13, 2003

7
FDA Advisory Committee for Pharmaceutical Science—March 13, 2003 Carlos R. Hamilton, Jr. MD, FACE American Association of Clinical Endocrinologists—Vice President The University of Texas Health Science Center—Houston, Executive Vice-President for Clinical Affairs

Upload: siusan

Post on 10-Feb-2016

37 views

Category:

Documents


0 download

DESCRIPTION

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003. Carlos R. Hamilton, Jr. MD, FACE American Association of Clinical Endocrinologists—Vice President The University of Texas Health Science Center—Houston, Executive Vice-President for Clinical Affairs . - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

FDA Advisory Committee for Pharmaceutical Science—March 13,

2003

Carlos R. Hamilton, Jr. MD, FACE American Association of Clinical Endocrinologists—Vice President

The University of Texas Health Science Center—Houston, Executive Vice-President for Clinical Affairs

Page 2: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

American Association of Clinical Endocrinologists

A professional organization representing over 4000 physicians specializing in the care of patients

with disorders of the endocrine system and with metabolic

diseases. These are the specialists called on by our colleagues for

care of patients with thyroid and other glandular disorders. Hence we have an acute awareness of

the effects of thyroid replacement medication.

Page 3: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

3

Significant Clinical Effects May Result from Mild Degrees of either Over-

Replacement (Hyperthyroidism) or Under-Replacement (Hypothyroidism) of Thyroid

Hormone in Treated Patients• Hyperthyroidism• Irregular or rapid heart rhythm• Accelerated osteo- porosis• Muscle weakness and weight loss• Psychiatric

symptoms• etc.

• Hypothyroidism• Premature ischemic heart disease• High cholesterol• Abnormal weight

gain• Menstrual changes• Fatigue and

lethargy• etc.

Page 4: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

4

Measurement of the Serum TSH Level is the Gold Standard for Evaluating

Effective Levels of Circulating Thyroid Hormone

• Much more precise and sensitive than measurement of the actual thyroid hormone (L-thyroxine or T-3).

• TSH (thyroid stimulating hormone or thyrotropin) is produced by the pituitary gland and increases when the effective thyroid levels are lower than ideal and decreases when thyroid levels are excessive.

• Serum TSH level is very sensitive to changes in effective thyroid hormone blood levels and is the most accurate guide to finding the optimal dosage of thyroid hormone medication for a particular patient.

Page 5: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

5

Dosage Changes of as Little as 12.5 to 25 Micrograms of Oral L-

Thyroxine Daily Have Significant Effects on Serum TSH

• These changes, whether from change in dose or brand, can have important clinical effects on our patients.

• Excessive amounts can cause symptoms and effects of hyperthyroidism.

• Sub-optimal amounts can cause symptoms and effects of hypothyroidism.

Page 6: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

6

Effects of L-Thyroxine Dosage Changes on Serum TSH Levels

Carr D, et al. Fine Adjustment of Thyroxine Replacement Dosage: Comparison of the Thyrotropin Releasing Hormone Test Using a Sensitive Thyrotropin Assay with Measurement of Free Thyroid Hormones and Clinical Assessment. Clinical Endocrinology, 1998, 28: 325-333.

Page 7: FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

7

Importance of these Observations for the Management of Patients Requiring

Thyroid Hormone Replacement• When the dosage, source or brand of thyroid

hormone replacement is changed, one should re-check serum TSH levels in 6-8 weeks to verify the effectiveness of the new preparation.

• Changes from one brand or manufacturer of L-thyroxine should be followed by a re-check of serum TSH to verify their equivalence.

• When the same dose and source of thyroid is used, one needs to re-check only at yearly intervals.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. Endocrine Practice 8:457, 2002.